Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

t fully controlled despite treatment with one or two other antiepileptic drugs. The third study is a randomized, double-blind, placebo-controlled trial with flexible dosing designed to evaluate the safety and tolerability of brivaracetam in patients with uncontrolled partial onset or primary generalized seizures. First results of these studies are expected in mid 2009.

About Brivaracetam: Brivaracetam has distinct pharmacological differences as well as having some structural similarity to the AED Keppra(R) (levetiracetam). In preclinical studies brivaracetam was shown to have a 10- fold higher affinity for synaptic vesicle protein 2A (SV2A) than Keppra(R). Brivaracetam also has inhibitory activity at neuronal voltage-dependent sodium channels whose abnormal function is understood to contribute to electrical discharges associated with seizures. These differences may explain brivaracetam's antiepileptic activity, clinical efficacy and tolerability.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting more than 2.5 million Americans regardless of race, age or sex. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or have significant adverse side effects secondary to medication, highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the U.S.: Keppra(R) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in JME
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... intensive care units (NICU) set up private rooms for parents ... Researchers at one children,s hospital found that preemies gained ... their NICU switched from the traditional "open-bay" layout to private ... in the journal Pediatrics , add to evidence that ...
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... Many American parents are aware of online physician-rating sites, and ... for their children, according to a new national study. ... parents -- further suggest that negative online ratings may dissuade ... been recommended by a neighbor. Conversely, a positive online ...
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... scientists have found that an anticonvulsant drug may help ... Although dozens of antibiotics target what bacteria do, their ... bacteria are created, and they found there is a ... important as there is growing concern worldwide about how ... The World Health Organization has declared that antibiotic resistance ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Looking ahead: Whole eye transplant under development 2
... body of basic animal research and studies of abused ... for the hypothesis that individuals with particular genotypes are ... with the abuse of alcohol and other substances. ... assume that these genotypes identify people who are predestined ...
... Board of Directors Audit Committee Members and Complies with ... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... J. Wilson as vice president of finance and principal ... team. She brings over twenty years of finance ...
... of Suntan Lotions, Reducing Risk of Deadly Skin Cancer ... & Prevention MonthNEW YORK, April 29 The ... people avoid overexposure to harmful ultraviolet radiation from the ... all across America reduce the risk of skin cancer ...
... 23-month-old child in Texas; CDC warns more deaths are ... 23-month-old child in Texas has become the first U.S. ... officials said Wednesday morning. , Dr. Richard Besser, acting ... Prevention, confirmed the death. No other details on the ...
... Dr. Gordon Norman presents overview of US healthcare ... Federation of Health Plans Meeting in Boston- Noted ... value for its healthcare investment- Emphasized greater coordination ... resolve today,s healthcare challenges MARIETTA, Ga., April 29 ...
... & Mentally IllNEW YORK, April 29 May marks ... it, philanthropic-minded New Yorkers will raise money for Weston ... and physically disabled. As federal and state funding ... the current economy, supporters will raise funds amidst live ...
Cached Medicine News:Health News:Genetic risk for anxiety does not have to be destiny 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 3Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 2Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 3Health News:Weston United Celebrates Mental Health Month on May 19th 2
(Date:9/22/2014)... CORONA, Calif. , Sept. 22, 2014  AVT, ... in automated retailing systems and custom vending machines, announced ... Opticwash Pro Unit. This new, smaller sized unit is ... Professional (ECP) practices. According to industry statistics, ... Opticwash is the world,s first ...
(Date:9/22/2014)... 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... Emory University, presented long-term follow up data on the ... in the treatment of amyotrophic lateral sclerosis (ALS or ... at the Annual Symposium on ALS of the Foundation ... Friday, and was not open to the public, covered ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... fourth quarter and fiscal 2014 ended July 31, 2014 on ... conference call to discuss the results at 11:00 AM ET. ... , Chairman; Andrew A. Krakauer , President and CEO; ... Craig A. Sheldon , Senior Vice President, CFO and ...
Breaking Medicine Technology:Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
... proteins that suppress the secretion of FSH ... consists of two distinct chains, or subunits ... consists of the alpha-subunit and betaA-subunit. Inhibin ... Only the dimeric forms of the molecule, ...
Medicine Products: